HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Antiplatelet

Post TAVR Aspirin vs. Clopidogrel: Conflicting Findings and Guidelines

One month ago we shared a meta-analysis stating aspirin (ASA) as the best antiplatelet following TAVR vs....
solaci -
Learn More
Institutional News

06/10 | SOLACI Webinar – Pressure Gradients After TAVR: Paradigm Shift?

solaci -
Learn More
Institutional News

Webinar SOLACI | TAVI Optimizing Implanting Techniques in Challenging Scenarios

solaci -
Learn More
Structural heart disease

EuroPCR 2021 | Evolut Low Risk: Two-Year Results of The Self-Expanding Valve in Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with...
solaci -
Learn More
STRUCTURAL HEART DISEASE

EuroPCR 2021 | TVT Registry: Outcomes of TAVR in Low Surgical Risk Bicuspids

In bicuspid patients with aortic stenosis and low surgical risk, transcatheter aortic valve replacement (TAVR) with balloon...
solaci -
Learn More
STRUCTURAL HEART DISEASE

EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System

The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low...
solaci -
Learn More
Structural heart disease

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet...
solaci -
Learn More
Antithrombotic Anticoagulants

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard...
solaci -
Learn More